Dermata Therapeutics, Inc. (DRMAW)
DRMAW Stock Price Chart
Explore Dermata Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DRMAW price movements and trends.
DRMAW Company Profile
Discover essential business fundamentals and corporate details for Dermata Therapeutics, Inc. (DRMAW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Aug 2021
Employees
8.00
Website
http://www.dermatarx.comCEO
Gerald T. Proehl
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
DRMAW Financial Timeline
Browse a chronological timeline of Dermata Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
EPS came in at -$1.66 surpassing the estimated -$2.90 by +42.86%.
Earnings released on 14 May 2025
EPS came in at -$0.45 surpassing the estimated -$4.50 by +90.07%.
Earnings released on 30 Sept 2023
EPS came in at -$0.54 .
Earnings released on 30 Jun 2023
EPS came in at -$1.73 .
Earnings released on 31 Mar 2023
Earnings released on 31 Dec 2022
EPS came in at -$0.13 .
DRMAW Stock Performance
Access detailed DRMAW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.